Abstract
Somatostatin was isolated from extracts of ovine1 and porcine2 hypothalamic tissue and was found to be a cyclic tetradecapeptide with the following sequence: {A figure is presented} Subsequent studies revealed that the peptide not only had inhibiting effects on growth hormone (GH) release, but also on pituitary thyrotropin (TSH) and a large array of gastrointestinal and pancreatic hormones, including insulin, glucagon, gastrin and gastric acid, secretin, CCK, GIP, VIP, and motilin. These activities have been recently reviewed.3. The therapeutic value of somatostatin in several important areas is diminished by its broad spectrum of activities. As with most naturally occurring peptides, somatostatin also has a short biologic half-life, 4 making its long-term use impractical. Therefore, analogues are being designed for enhanced, prolonged, and selective activities. In addition, competitive inhibitors of somatostatin could be of great interest and pharmacologic value.
| Original language | English |
|---|---|
| Pages (from-to) | 1407-1410 |
| Number of pages | 4 |
| Journal | Metabolism |
| Volume | 27 |
| Issue number | 9 SUPPL. 1 |
| DOIs | |
| State | Published - Jan 1 1978 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Endocrinology
- Endocrinology, Diabetes and Metabolism
Cite this
Observations on the growth hormone, insulin, and glucagon release-inhibiting activities of somatostatin analogues. / Coy, David H.; Meyers, Chester; Arimura, Akira; Schally, Andrew V; Redding, Tommie W.
In: Metabolism, Vol. 27, No. 9 SUPPL. 1, 01.01.1978, p. 1407-1410.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Observations on the growth hormone, insulin, and glucagon release-inhibiting activities of somatostatin analogues
AU - Coy, David H.
AU - Meyers, Chester
AU - Arimura, Akira
AU - Schally, Andrew V
AU - Redding, Tommie W.
PY - 1978/1/1
Y1 - 1978/1/1
N2 - Somatostatin was isolated from extracts of ovine1 and porcine2 hypothalamic tissue and was found to be a cyclic tetradecapeptide with the following sequence: {A figure is presented} Subsequent studies revealed that the peptide not only had inhibiting effects on growth hormone (GH) release, but also on pituitary thyrotropin (TSH) and a large array of gastrointestinal and pancreatic hormones, including insulin, glucagon, gastrin and gastric acid, secretin, CCK, GIP, VIP, and motilin. These activities have been recently reviewed.3. The therapeutic value of somatostatin in several important areas is diminished by its broad spectrum of activities. As with most naturally occurring peptides, somatostatin also has a short biologic half-life, 4 making its long-term use impractical. Therefore, analogues are being designed for enhanced, prolonged, and selective activities. In addition, competitive inhibitors of somatostatin could be of great interest and pharmacologic value.
AB - Somatostatin was isolated from extracts of ovine1 and porcine2 hypothalamic tissue and was found to be a cyclic tetradecapeptide with the following sequence: {A figure is presented} Subsequent studies revealed that the peptide not only had inhibiting effects on growth hormone (GH) release, but also on pituitary thyrotropin (TSH) and a large array of gastrointestinal and pancreatic hormones, including insulin, glucagon, gastrin and gastric acid, secretin, CCK, GIP, VIP, and motilin. These activities have been recently reviewed.3. The therapeutic value of somatostatin in several important areas is diminished by its broad spectrum of activities. As with most naturally occurring peptides, somatostatin also has a short biologic half-life, 4 making its long-term use impractical. Therefore, analogues are being designed for enhanced, prolonged, and selective activities. In addition, competitive inhibitors of somatostatin could be of great interest and pharmacologic value.
UR - http://www.scopus.com/inward/record.url?scp=0018072227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018072227&partnerID=8YFLogxK
U2 - 10.1016/0026-0495(78)90083-5
DO - 10.1016/0026-0495(78)90083-5
M3 - Article
C2 - 683009
AN - SCOPUS:0018072227
VL - 27
SP - 1407
EP - 1410
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
SN - 0026-0495
IS - 9 SUPPL. 1
ER -